MENLO PARK, CA--(MARKET WIRE)--Aug 7, 2006 -- XTENT, Inc. announced today it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. Copies of XTENT’s S-1 Registration Statement can be accessed over the Internet through the SEC’s web site at www.sec.gov. All shares of the common stock to be sold in this offering will be sold by XTENT, Inc.
XTENT is a medical device company focused on the development and commercialization of innovative customizable drug eluting stent systems for the treatment of coronary and peripheral artery disease.
Piper Jaffray & Co. will be acting as the book-running manager and Cowen and Company LLC, Lazard Capital Markets LLC, and RBC Capital Markets are acting as co-managers. The numbers of shares to be offered and the price range have not yet been determined. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402.
A registration statement relating to these securities has been filed with the SEC, but it has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction.
This news release contains certain forward-looking statements that involve risks and uncertainties. Forward-looking statements include XTENT’s plans to sell securities in an initial public offering. Such statements are only predictions and actual results may differ materially from those anticipated in these forward-looking statements.
Contact: For further information, contact: Tim Kahlenberg CFO XTENT, Inc. Phone: (650) 475-9400
Source: XTENT, Inc.
